Vici et al26
|
G 1500 mg/m2 d1, 15 + T150 mg/m2 d1, 15 q4wks
|
20
|
45% (10%)
|
8
|
Heavily pretreated pts; supported with G-CSF
|
Colomer et al27
|
G 2500 mg/m2 d1 + T150 mg/m2 d1 q2wks
|
43
|
68% (21%)
|
9
|
Previously treated pts; hematologic toxicity
|
Delfino et al28
|
G 1200 mg/m2 d1, 8 + T 175 mg/m2 d1 q3wks
|
45
|
67% (22%)
|
11
|
Chemonaïve pts; mild hematologic toxicity; manageable toxicity
|
Sanchez-Rovira et al29
|
G 2500 mg/m2 d1, 15 + T 135 mg/m2 d1, 15 q4wks
|
44
|
45% (7%)
|
7
|
Previously treated pts; hematologic and neurologic toxicities
|
Murad et al30
|
G 1000 mg/m2 d1, 8 + T 175 mg/m2 d1 q3wks
|
29
|
55% (17%)
|
8
|
Heavily pretreated pts; 28-day reduced to a 21-day schedule due to hematologic toxicity
|
Genot et al (current study)
|
G 1200 mg/m2 d1, 8 T 175 mg/m2 d1 q3wks
|
40
|
40% (5.7%)
|
7.2
|
No prior treatment for metastatic disease, neutropenia prominent, other toxicities mild
|